Short Communication Anti-HIV-1 activity determined by b-galactosidase activity in the multinuclear activation of an indicator assay is comparable with that by a conventional focus counting method Antiviral Chemistry and Chemotherapy 2015, Vol. 24(2) 77 82! The Author(s) 2015 Reprints and permissions: sagepub.co.uk/journalspermissions.nav DOI:.1177/2040206615614164 avc.sagepub.com Fusako Miyamoto 1,2, Kumi Kawaji 1,2, Shinya Oishi 3, Nobutaka Fujii 3, Mitsuo Kaku 2 and Eiichi N Kodama 1,2 Abstract Background: Direct comparison of enzymatic and original blue cell-counting detections with the multinuclear activation of an indicator (MAGI) cells, so far, remains to be performed in parallel. Although inhibitors for reverse transcription solely inhibit the reverse transcription step, those for HIV-1 entry block syncytium formation of HIV-1-infected MAGI cells in addition to the entry (dual inhibition). It raises a concern that reduction of enzymatic activity is artificially influenced by syncytium-blocking activity of inhibitors for entry. Methods: The MAGI cells with a syncytium inducible strain, HIV-1 IIIB, were used for anti-hiv activity determination both with conventional counting with X-Gal staining and measurement of chlorophenol red b-d-galactopyranoside conversion with a plate reader. Results: Infectivity of HIV-1 in the MAGI cells was highly correlated with both methods. In microscopic observation, small blue cells with single or a couple of nuclei were dominantly observed in the presence of inhibitors for entry, but not in the presence of those for reverse transcription. Actual anti-hiv-1 activities were comparable or moderately sensitive in the chlorophenol red b-d-galactopyranoside method. Conclusions: Antiviral activities of inhibitors for entry obtained from both enzymatic and counting methods appear to be comparable, even in infection of a highly syncytia inducible HIV-1 IIIB strain. Keywords Enzyme, sensitivity, screening, entry inhibitor, reverse-transcriptase inhibitor Introduction The MAGI assay providing accurate infectivity of HIV-1 is established as a simple and rapid system to screen compounds blocking HIV-1 replication. 1 4 However, to evaluate HIV infectivity, it requires tedious counting, which hampers wide application of the MAGI assay to high throughput screenings. Therefore, simple and automated enzymatic assay systems have been developed, such as an assay with TZM-bl cells, which are HeLa-derived cells expressing high expression of CD4 and CCR5 by amphotropic retroviral transduction and containing an HIV-1 transactivator protein, Tat-responsive two reporter genes, firefly luciferase and b-galactosidase, for a sensitive quantitation 1 Division of Miyagi Community Health Promotion, Tohoku University Graduate School of Medicine and Tohoku Medical Megabank Organization, Sendai, Japan 2 Division of Infection Control and Laboratory Diagnostics, Department of Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan 3 Graduate School of Pharmaceutical Science, Kyoto University, Kyoto, Japan Corresponding author: Eiichi N Kodama, Division of Miyagi Community Health Promotion, Tohoku University School of Medicine, Building 1, Room #515, 2-1 Seiryocho, Aoba-ku, Sendai 980-8575, Japan. Email: kodama515@med.tohoku.ac.jp
78 Antiviral Chemistry and Chemotherapy 24(2) of HIV-1 infection. 5,6 For instance, Maeda et al. evaluated antiviral activity of CCR5 antagonists by enzymatic activity of b-galactosidase with the MAGI cells. 7 In general, these assays provide relatively high throughput screenings with convenient protocols. There is a concern on correlation whether counting and enzymatic methods for the evaluation of antiviral activities are comparable. For instance, inhibitors for the reverse transcription (RT), they solely inhibit the RT step, while those for entry can block two steps, syncytium formation at the late replication step in addition to the entry step. The single-round MAGI assay indeed detects only antiviral activity of early steps, since it utilizes 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-Gal) conversion by expression of LTRdriven b-galactosidase through Tat 2. In this regard, syncytium formation that takes place in the late phase of HIV replication is also blocked by inhibitors for entry, resulting in production of small blue cells. In the counting method, either small or large infective focus will be counted as one infection focus, while in enzymatic assay, small syncytia produce less enzymatic activity, led to possible artificially influenced antiviral activity. To our best knowledge, there are no comparison in antiviral activity obtained from methods by microscopic counting and enzymatic activity. Here, we compared both methods with HIV-1 IIIB and HIV-1 NL4-3, which produce high-level syncytia with its infection, to investigate inhibitory effect of syncytia formation on the antiviral activity. Methods Cells and viruses HeLa-CD4-LTR-b-gal cells 2 were kindly provided by Dr. M. Emerman through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Disease (Bethesda, MD), and used for the antiviral assay as previously described. 8,9 A laboratory wild-type stain, HIV-1 IIIB was propagated in MT-2 cells, harvested and stored at 80 C as described previously. 3 Recombinant infectious clones of HIV-1 carrying various mutations in the pol gene were generated using pnl1 as previously described. 1 Each molecular clone (2 mg/ml as DNA) was transfected into 293 T cells using the TransIT-LT1 Transfection Reagent (Mirus Bio, Madison, WI). After 24 h incubation, MT-2 cells ( 6 cells/well) were added and co-cultured with 293 T cells for an additional 24 h. When an extensive cytopathic effect was observed, the cell supernatants were harvested and stored at 80 C until further use. Antiviral agents An adsorption inhibitor, dextran sulfate MW 5000 (DS5000) and an HIV-1 nucleoside reverse-transcriptase inhibitor, 3 0 -azido-3 0 -deoxythymidine (AZT) was purchased from Sigma-Aldrich Japan (Tokyo, Japan). A non-nucleoside reverse-transcriptase inhibitor, efavirenz, was obtained through the NIH AIDS Reagent Program. A CXCR4 antagonist, AMD30 was kindly provided from Prof. Shiro Shigeta, Fukushima Medical University (Fukushima, Japan). Peptide-based HIV-1 fusion inhibitors were chemically synthesized using standard Fmoc-based solid-phase techniques, as previously described.,11 Determination of drug susceptibility Drug susceptibility with counting was determined as previously described. 8,9 Briefly, HeLa-CD4-LTR-b-gal cells were plated in flat 96-well culture plates ( 4 cells/ well). On the following day, the cells were inoculated with HIV-1 IIIB (60 blue cell-forming units (BFU)/well, resulting into 60 blue cells after 48 h incubation) and cultured in the presence of drugs. Forty-eight hours after virus inoculation, the cells were fixed with phosphate-buffered saline (PBS) containing 1% formaldehyde and 0.2% glutaldehide for 5 min, washed with PBS three times, and incubated with 0.4 mg/ml X- Gal, 4 mm potassium ferricyanide, 4 mm potassium ferrocyanide, and 2 mm of MgCl 2 in PBS for 1 h at 37 C. All the blue cells stained with X-gal were counted in each well. The activity of compounds was determined as the concentration that reduced HIV-1 infection by 50% (EC 50 ). Drug susceptibility with enzymatic activity was also determined as described 7 with some modifications. Briefly, the assay was performed as identical to the counting method, except for the amount of HIV-1 IIIB inoculation (300 BFU/well) due to low color development in the spectrometer. After 48 h of HIV-1 inoculation, cells incubated for were lysed with PBS containing 1% Triton-X0 (0 ml) and incubated at 37 C for 1 h with mm chlorophenol red b-d-galactopyranoside (CPRG) in 2 mm MgCl 2, and 0 mm KH 2 PO 4 (0 ml). To terminate the reaction, 80 ml of 0.5 M Na 2 CO 3 was added. The optical density (wavelength at 570 nm) was measured in a microplate reader (GloMax Õ -Multiþ Microplate Multimode Reader, Promega Corporation, Madison, WI). Drug concentrations that brought about 50% inhibition of the b-galactosidase activity were determined. The amount of HIV-1 p24 gag antigen level representing viral particle was determined on day 2 with a commercially available ELISA kit (RETRO Tek HIV-1 p24 antigen ELISA 2.0, ZeptoMtrix Co., Buffalo, NY)
Miyamoto et al. 79 and compared with infectivity examined by a counting method. All assays were performed in triplicate. Results Microscopic observation A representative syncytium-inducible stain, HIV-1 IIIB, infected MAGI cells in the presence of inhibitors for entry and RT (non-entry) just after 48 h post infection were stained with X-Gal and shown in Figure 1. Two RT inhibitors, AZT and EFV, that are incapable of inhibition of syncytium formation, showed large and apparent syncytia as shown in control but the number of foci was apparently reduced. In contrast, infected foci under entry inhibitors, DS5000, AMD30, and C34, were apparently small and sometimes only consisted of single cells. These results suggest that, depending on the mechanism of action, antiviral activity obtained from counting and enzymatic methods might be artificially influenced between two methods. Correlation of infectivity First, we examined the correlation of the infectivity obtained from counting and enzymatic methods. In the counting method, in a 96-well plate, blue cells indicating HIV-1 infected cells are adjusted to 60 BFU/well to count conveniently with enough accuracy, 3,4 since too low viral input makes difficult to obtain accurate data but too many makes difficult to count. However, in the enzymatic assay, it is somewhat not sufficient to generate enough optical density with the CPRG substrate. As shown in Figure 2(a), to produce efficient optical density with CPRG conversion (approximately 1.0) over 300 BFU/well appeared to be required. At least up to 320 BFU/well, correlation of both methods was well maintained (R 2 ¼ 0.9839). Therefore, in the absence of inhibitors, both methods are highly correlated with each other. For further confirmation, we examined correlation between the counting and amount of p24 antigen level. Infectivity by the counting and ELISA methods was well correlated (R 2 ¼ 0.9999, Figure 2(b)). Comparison of antiviral activity Antiviral activities of inhibitors for entry and RT (nonentry) obtained from both methods were compared in parallel. Activities of AZT, and EFV were relatively enhanced in the enzymatic method without statistical significance (Student s t-test; p > 0.05), compared with entry inhibitors that block syncytia formation (Figure 2(c)). A fusion inhibitor, C34 that blocks entry and syncytium formation, seems to show relative enhanced activity in the enzymatic method. Therefore, we further examined other fusion inhibitors, a clinically approved T-20 (Fuzeon) and its derivatives, T-20 S138A and T-20EK 12,13 and a C34 derivative SC35EK. 9 Activities of all fusion inhibitors determined by the both methods were comparable (Figure 2(d)). DS5000 AMD30 C34 Control AZT EFV 0 μm Figure 1. Syncytia in the presence of inhibitors. After 48 h the MAGI cells infected with HIV-1 IIIB in the presence of inhibitors were fixed and stained with X-Gal. HIV-1 IIIB infected cells were indicated as cells with dark blue-stained nuclei. In the absence of inhibitors, HIV-1 IIIB -infected cells formed large syncytia. In the presence of inhibitors for entry and RT (non-entry inhibitors), size of syncytia appears smaller and similar, respectively, but number is decreased in all inhibitors, which concentrations were used at EC 50. Inhibitors for entry, DS5000, AMD30, and C34 block steps of adsorption, co-receptor (CXCR4) interaction, and fusion, respectively. AZT and EFV block RT step competitively and allosterically, respectively.
80 Antiviral Chemistry and Chemotherapy 24(2) (a) 1.2 (b) β-gal activity (OD) 1.0 0.8 0.6 0.4 0.2 R² = 0.9839 p24 antigen (ng/ml) 8 6 4 2 R 2 = 0.9999 0 0 0 200 300 400 0 0 50 0 150 200 250 Blue cell forming unit Blue cell forming unit (c) 0 (d) 200 0 EC 50 (nm) 1 EC50 (nm) 0.1 DS 5000 AMD 30 T-20 C34 AZT EFV 1 T-20 T-20 S138A T-20EK C34 SC35EK Adsorption Fusion RT reaction (e) 000 00 EC 50 (nm) 0 1 0.1 AZT EFV AZT EFV NL 4-3 WT NL 4-3 AZT-R Figure 2. Comparison of counting and enzymatic methods. Correlation of infectivity obtained from counting (X-axis) and enzymatic (Y-axis) methods (a), and that from counting (X-axis) and amount of p24 antigen ELISA (Y-axis) methods (b) are shown. Correlations were calculated by Pearson s correlation method. Anti-HIV activity data (EC 50 value) obtained from both methods were compared (c). Inhibitors for entry, DS5000, AMD30, and C34 block steps of adsorption, co-receptor (CXCR4) interaction, and fusion, respectively. AZT and EFV block RT step competitively and allosterically, respectively. Various fusion inhibitors were also examined (d). Antiviral activities for AZT-sensitive (wild type) and AZT-resistant NL4-3 based HIV-1 clones were also examined (e). Antiviral activities shown (c, d, and e) were well comparable (not significant by Student s t-test). Black and white bars indicate EC 50 values by counting and enzymatic methods, respectively.
Miyamoto et al. 81 We further examined with two HIV-1 NL4-3 -based viruses, wild- and AZT-resistant clones. AZT resistant HIV-1 NL4-3 virus containing the resistance mutations in the RT coding region (M41L/D67N/K70E/V75M/ L2W/T215Y) and shows high-level resistance to AZT but not to EFV. As shown in Figure 2(e), activities of AZT and EFV were comparable in NL4-3 based HIV-1 viruses. Taken together, the antiviral activity of various compounds obtained from both methods is well comparable. Discussion In this study, we compared two representative methods for the detection of HIV-1 infectivity in the MAGI cells in parallel. In the counting method, either small or large syncytia will be counted as one infective focus, while in the enzymatic method, small and large syncytia may produce low and high enzymatic activity, respectively. It is likely that inhibitors for HIV-1 entry might show artificially enhanced activity due to dual mechanisms of action, inhibition of syncytium formation in addition to entry per se. It will make it difficult to compare or evaluate antiviral activity obtained from the two distinct methods. However, anti-hiv activity was, surprisingly, comparable in both methods. It is likely that relatively high input of HIV-1 in 96-well plate (300 MU/well) may reduce or interfere with formation of large syncytia, since adjacent cells may also be infected with HIV-1. Since b-galactosidase system is well established and can be visualized with X-Gal staining, it will be convenient to standardize HIV infectivity, or titer and suitable to compare characteristics of both methods. Moreover, the b-galactosidase activity can be measured by various commercial available systems. Here, we applied CPRG to detect enzyme activity and successfully detect their activity with a standard spectrometer. This enables to detect even in a resource-limited laboratory. Probably, luciferase system with TZM-bl cells must be more sensitive but it needs luminometer and relatively expensive luciferase substrate, 14 while a CRPG/b-galactosidase system is simple and widely useful for various applications. In conclusion, we compared counting and enzymatic methods with the MAGI cells and revealed that both systems will work and detect comparable antiviral activity. Acknowledgements We are grateful to the Network Joint Research Center for Materials and Devises and the Biomedical Research Core (Tohoku University Institute of Multidisciplinary Research for Advanced Materials, and Graduate School of Medicine, respectively) for technical support. Declaration of conflicting interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by a grant from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, a grant for the Promotion of AIDS Research from the Ministry of Health, Labour and Welfare. References 1. Kawamoto A, Kodama E, Sarafianos SG, et al. 2 0 -deoxy- 4 0 -C-ethynyl-2-halo-adenosines active against drug-resistant human immunodeficiency virus type 1 variants. Int J Biochem Cell Biol 2008; 40: 24 2420. 2. Kimpton J and Emerman M. Detection of replicationcompetent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992; 66: 2232 2239. 3. Kodama EI, Kohgo S, Kitano K, et al. 4 0 -Ethynyl nucleoside analogs: potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001; 45: 1539 1546. 4. Maeda Y, Venzon DJ and Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998; 177: 1207 1213. 5. Derdeyn CA, Decker JM, Sfakianos JN, et al. Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 2000; 74: 8358 8367. 6. Platt EJ, Wehrly K, Kuhmann SE, et al. Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1. J Virol 1998; 72: 2855 2864. 7. Maeda K, Yoshimura K, Shibayama S, et al. Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem 2001; 276: 35194 35200. 8. Nameki D, Kodama E, Ikeuchi M, et al. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions. J Virol 2005; 79: 764 770. 9. Nishikawa H, Nakamura S, Kodama E, et al. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide. Int J Biochem Cell Biol 2009; 41: 891 899.. Oishi S, Ito S, Nishikawa H, et al. Design of a novel HIV- 1 fusion inhibitor that displays a minimal interface for binding affinity. J Med Chem 2008; 51: 388 391.
82 Antiviral Chemistry and Chemotherapy 24(2) 11. Otaka A, Nakamura M, Nameki D, et al. Remodeling of gp41-c34 peptide leads to highly effective inhibitors of the fusion of HIV-1 with target cells. Angew Chem Int Ed Engl 2002; 41: 2937 2940. 12. Izumi K, Kawaji K, Miyamoto F, et al. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design. Int J Biochem Cell Biol 2013; 45: 908 915. 13. Shimane K, Kawaji K, Miyamoto F, et al. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains. Antimicrob Agents Chemother 2013; 57: 4035 4038. 14. Wei X, Decker JM, Liu H, et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896 1905.